New combo therapy battles advanced kidney cancer in major trial
NCT ID NCT04394975
First seen Nov 28, 2025 · Last updated Apr 06, 2026 · Updated 16 times
Summary
This large, completed Phase 3 trial compared a new two-drug combination (toripalimab plus axitinib) against the standard single-drug therapy (sunitinib) for people with advanced kidney cancer that cannot be removed by surgery. The main goal was to see if the combination could keep the cancer from growing for a longer time. The study involved 421 adults who had not received prior drug treatment for their advanced cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY DISEASE: UNRESECTABLE OR METASTATIC RENAL CELL CARCINOMA FOCUS OF THE STUDY:PFS ASSESSED BY IRC PER RECIST 1.1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.